Celiac Disease and its Therapy: Current Approaches and New Advances

Wheat and Rice in Disease Prevention and Health

Volumn , Issue , 2014, Pages 143-155

  Nehra, Vandana ^a   Marietta, Eric V ^a   Murray, Joseph A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Celiac disease; Dermatitis herpetiformis; Gliadin; Gluten; Gluten free diet; Small bowel biopsy; Wheat

Indexed keywords

EID: 84903240359     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-401716-0.00012-X     Document Type: Chapter

References (147)

1. Ludvigsson J., Rubio-Tapia A., van Dyke C.T., Melton L.J., Zinsmeister A.R., Lahr B.D., et al. Increasing incidence of Celiac Disease in North American Population. Am J Gastroenterol May 2013, (in press).
2. West J., Logan R.F., Smith C.J., Hubbard R.B., Card T.R. Malignancy and mortality in people with coeliac disease: population based cohort study. BMJ 2004, 329(7468):716-719.
3. Green P.H., Fleischauer A.T., Bhagat G., Goyal R., Jabri B., Neugut A.I. Risk of malignancy in patients with celiac disease. Am J Med 2003, 115(3):191-195.
4. Rubio-Tapia A., Rahim M.W., See J.A., Lahr B.D., Wu T.T., Murray J.A. Mucosal recovery and mortality in adults with celiac disease after treatment with a gluten-free diet. Am J Gastroenterol 2010, 105(6):1412-1420.
5. Tack G.J., Verbeek W.H., Schreurs M.W., Mulder C.J. The spectrum of celiac disease: epidemiology, clinical aspects and treatment. Nat Rev Gastroenterol Hepatol 2010, 7(4):204-213.
6. Dube C., Rostom A., Sy R., Cranney A., Saloojee N., Garritty C., et al. The prevalence of celiac disease in average-risk and at-risk Western European populations: a systematic review. Gastroenterology 2005, 128(4 Suppl. 1):S57-S67.
7. Cranney A., Rostom A., Sy R., Dube C., Saloogee N., Garritty C., et al. Consequences of testing for celiac disease. Gastroenterology 2005, 128(4 Suppl. 1):S109-S120.
8. Catassi C., Kryszak D., Bhatti B., Sturgeon C., Helzlsouer K., Clipp S.L., et al. Natural history of celiac disease autoimmunity in a USA cohort followed since 1974. Ann Med 2010, 42(7):530-538.
9. Rubio-Tapia A., Kyle R.A., Kaplan E.L., Johnson D.R., Page W., Erdtmann F., et al. Increased prevalence and mortality in undiagnosed celiac disease. Gastroenterology 2009, 137(1):88-93.
10. Scanlon S.A., Murray J.A. Update on celiac disease - etiology, differential diagnosis, drug targets, and management advances. Clin Exp Gastroenterol 2011, 4:297-311.
11. Corazza G.R., Valentini R.A., Andreani M.L., D'Anchino M., Leva M.T., Ginaldi L., et al. Subclinical coeliac disease is a frequent cause of iron-deficiency anaemia. Scand J Gastroenterol 1995, 30(2):153-156.
12. Stenson W.F., Newberry R., Lorenz R., Baldus C., Civitelli R. Increased prevalence of celiac disease and need for routine screening among patients with osteoporosis. Arch Intern Med 2005, 165(4):393-399.
13. Hadjivassiliou M., Rao D.G., Wharton S.B., Sanders D.S., Grunewald R.A., Davies-Jones A.G. Sensory ganglionopathy due to gluten sensitivity. Neurology 2010, 75(11):1003-1008.
14. Volta U., Ravaglia G., Granito A., Forti P., Maioli F., Petrolini N., et al. Coeliac disease in patients with autoimmune thyroiditis. Digestion 2001, 64(1):61-65.
15. Choi J.M., Lebwohl B., Wang J., Lee S.K., Murray J.A., Sauer M.V., et al. Increased prevalence of celiac disease in patients with unexplained infertility in the United States. J Reprod Med 2011, 56(5-6):199-203.
16. Ventura A., Magazzu G., Greco L. Duration of exposure to gluten and risk for autoimmune disorders in patients with celiac disease. SIGEP Study Group for Autoimmune Disorders in Celiac Disease. Gastroenterology 1999, 117(2):297-303.
17. Rostom A., Murray J.A., Kagnoff M.F. American Gastroenterological Association (AGA) Institute technical review on the diagnosis and management of celiac disease. Gastroenterology 2006, 131(6):1981-2002.
18. Villalta D., Girolami D., Bidoli E., Bizzaro N., Tampoia M., Liguori M., et al. High prevalence of celiac disease in autoimmune hepatitis detected by anti-tissue tranglutaminase autoantibodies. J Clin Lab Anal 2005, 19(1):6-10.
19. Volta U., Rodrigo L., Granito A., Petrolini N., Muratori P., Muratori L., et al. Celiac disease in autoimmune cholestatic liver disorders. Am J Gastroenterol 2002, 97(10):2609-2613.
20. Lindgren S., Sjoberg K., Eriksson S. Unsuspected coeliac disease in chronic 'cryptogenic' liver disease. Scand J Gastroenterol 1994, 29(7):661-664.
21. Abdulkarim A.S., Burgart L.J., See J., Murray J.A. Etiology of nonresponsive celiac disease: results of a systematic approach. Am J Gastroenterol 2002, 97(8):2016-2021.
22. Leffler D.A., Dennis M., Hyett B., Kelly E., Schuppan D., Kelly C.P. Etiologies and predictors of diagnosis in nonresponsive celiac disease. Clin Gastroenterol Hepatol 2007, 5(4):445-450.
23. Malamut G., Afchain P., Verkarre V., Lecomte T., Amiot A., Damotte D., et al. Presentation and long-term follow-up of refractory celiac disease: comparison of type I with type II. Gastroenterology 2009, 136(1):81-90.
24. Rubio-Tapia A., Kelly D.G., Lahr B.D., Dogan A., Wu T.T., Murray J.A. Clinical staging and survival in refractory celiac disease: a single center experience. Gastroenterology 2009, 136(1):99-107. quiz 352-3.
25. Ludvigsson J.F., Leffler D.A., Bai J.C., Biagi F., Fasano A., Green P.H., et al. The Oslo definitions for coeliac disease and related terms. Gut 2013, 62(1):43-52.
26. Verbeek W.H., Van De Water J.M., Al-Toma A., Oudejans J.J., Mulder C.J., Coupe V.M. Incidence of enteropathy-associated T-cell lymphoma: a nation-wide study of a population-based registry in The Netherlands. Scand J Gastroenterol 2008, 43(11):1322-1328.
27. Al-Toma A., Verbeek W.H., Hadithi M., von Blomberg B.M., Mulder C.J. Survival in refractory coeliac disease and enteropathy-associated T-cell lymphoma: retrospective evaluation of single-centre experience. Gut 2007, 56(10):1373-1378.
28. Daum S., Cellier C., Mulder C.J. Refractory coeliac disease. Best Pract Res Clin Gastroenterol 2005, 19(3):413-424.
29. Zone J.J., Meyer L.J., Petersen M.J. Deposition of granular IgA relative to clinical lesions in dermatitis herpetiformis. Arch Dermatol 1996, 132(8):912-918.
30. Collin P., Reunala T. Recognition and management of the cutaneous manifestations of celiac disease: a guide for dermatologists. Am J Clin Dermatol 2003, 4(1):13-20.
31. Zone J.J. Skin manifestations of celiac disease. Gastroenterology 2005, 128(4 Suppl. 1):S87-S91.
32. Caproni M., Antiga E., Melani L., Fabbri P. Guidelines for the diagnosis and treatment of dermatitis herpetiformis. J Eur Acad Dermatol Venereol 2009, 23(6):633-638.
33. Collin P., Pukkala E., Reunala T. Malignancy and survival in dermatitis herpetiformis: a comparison with coeliac disease. Gut 1996, 38(4):528-530.
34. Sener O., Doganci L., Safali M., Besirbellioglu B., Bulucu F., Pahsa A. Severe dapsone hypersensitivity syndrome. J Investig Allergol Clin Immunol 2006, 16(4):268-270.
35. Lewis N.R., Scott B.B. Systematic review: the use of serology to exclude or diagnose coeliac disease (a comparison of the endomysial and tissue transglutaminase antibody tests). Aliment Pharmacol Ther 2006, 24(1):47-54.
36. Chow M.A., Lebwohl B., Reilly N.R., Green P.H. Immunoglobulin A deficiency in celiac disease. J Clin Gastroenterol 2012, 46(10):850-854.
37. Cataldo F., Marino V., Ventura A., Bottaro G., Corazza G.R. Prevalence and clinical features of selective immunoglobulin A deficiency in coeliac disease: an Italian multicentre study. Italian Society of Paediatric Gastroenterology and Hepatology (SIGEP) and "Club del Tenue" Working Groups on Coeliac Disease. Gut 1998, 42(3):362-365.
38. Raivio T., Korponay-Szabo I., Collin P., Laurila K., Huhtala H., Kaartinen T., et al. Performance of a new rapid whole blood coeliac test in adult patients with low prevalence of endomysial antibodies. Dig Liver Dis 2007, 39(12):1057-1063.
39. Bienvenu F., Besson Duvanel C., Seignovert C., Rouzaire P., Lachaux A., Bienvenu J. Evaluation of a point-of-care test based on deamidated gliadin peptides for celiac disease screening in a large pediatric population. Eur J Gastroenterol Hepatol 2012, 24(12):1418-1423.
40. Lewis N.R., Scott B.B. Meta-analysis: deamidated gliadin peptide antibody and tissue transglutaminase antibody compared as screening tests for coeliac disease. Aliment Pharmacol Ther 2010, 31(1):73-81.
41. Rashtak S., Ettore M.W., Homburger H.A., Murray J.A. Comparative usefulness of deamidated gliadin antibodies in the diagnosis of celiac disease. Clin Gastroenterol Hepatol 2008, 6(4):426-432. quiz 370.
42. Dickey W., Hughes D.F., McMillan S.A. Disappearance of endomysial antibodies in treated celiac disease does not indicate histological recovery. Am J Gastroenterol 2000, 95(3):712-714.
43. Tursi A., Brandimarte G., Giorgetti G.M. Lack of usefulness of anti-transglutaminase antibodies in assessing histologic recovery after gluten-free diet in celiac disease. J Clin Gastroenterol 2003, 37(5):387-391.
44. Vahedi K., Mascart F., Mary J.Y., Laberenne J.E., Bouhnik Y., Morin M.C., et al. Reliability of antitransglutaminase antibodies as predictors of gluten-free diet compliance in adult celiac disease. Am J Gastroenterol 2003, 98(5):1079-1087.
45. Pais W.P., Duerksen D.R., Pettigrew N.M., Bernstein C.N. How many duodenal biopsy specimens are required to make a diagnosis of celiac disease?. Gastrointest Endosc 2008, 67(7):1082-1087.
46. Hopper A.D., Hadjivassiliou M., Hurlstone D.P., Lobo A.J., McAlindon M.E., Egner W., et al. What is the role of serologic testing in celiac disease? A prospective, biopsy-confirmed study with economic analysis. Clin Gastroenterol Hepatol 2008, 6(3):314-320.
47. Bonamico M., Thanasi E., Mariani P., Nenna R., Luparia R.P., Barbera C., et al. Duodenal bulb biopsies in celiac disease: a multicenter study. J Pediatr Gastroenterol Nutr 2008, 47(5):618-622.
48. Oberhuber G., Granditsch G., Vogelsang H. The histopathology of coeliac disease: time for a standardized report scheme for pathologists. Eur J Gastroenterol Hepatol 1999, 11(10):1185-1194.
49. Hadithi M., von Blomberg B.M., Crusius J.B., Bloemena E., Kostense P.J., Meijer J.W., et al. Accuracy of serologic tests and HLA-DQ typing for diagnosing celiac disease. Ann Intern Med 2007, 147(5):294-302.
50. Schuppan D., Junker Y., Barisani D. Celiac disease: from pathogenesis to novel therapies. Gastroenterology 2009, 137(6):1912-1933.
51. Catassi C., Rossini M., Ratsch I.M., Bearzi I., Santinelli A., Castagnani R., et al. Dose dependent effects of protracted ingestion of small amounts of gliadin in coeliac disease children: a clinical and jejunal morphometric study. Gut 1993, 34(11):1515-1519.
52. Catassi C., Fabiani E., Iacono G., D'Agate C., Francavilla R., Biagi F., et al. A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease. Am J Clin Nutr 2007, 85(1):160-166.
53. Lohiniemi S., Maki M., Kaukinen K., Laippala P., Collin P. Gastrointestinal symptoms rating scale in coeliac disease patients on wheat starch-based gluten-free diets. Scand J Gastroenterol 2000, 35(9):947-949.
54. Kaukinen K., Turjanmaa K., Maki M., Partanen J., Venalainen R., Reunala T., et al. Intolerance to cereals is not specific for coeliac disease. Scand J Gastroenterol 2000, 35(9):942-946.
55. Akobeng A.K., Thomas A.G. Systematic review: tolerable amount of gluten for people with coeliac disease. Aliment Pharmacol Ther 2008, 27(11):1044-1052.
56. Fasano A., Catassi C. Clinical practice. Celiac disease. N Engl J Med 2012, 367(25):2419-2426.
57. Aziz I., Evans K.E., Papageorgiou V., Sanders D.S. Are patients with coeliac disease seeking alternative therapies to a gluten-free diet?. J Gastrointestin Liver Dis 2011, 20(1):27-31.
58. Hogberg L., Grodzinsky E., Stenhammar L. Better dietary compliance in patients with coeliac disease diagnosed in early childhood. Scand J Gastroenterol 2003, 38(7):751-754.
59. Hall N.J., Rubin G., Charnock A. Systematic review: adherence to a gluten-free diet in adult patients with coeliac disease. Aliment Pharmacol Ther 2009, 30(4):315-330.
60. Kemppainen T., Kroger H., Janatuinen E., Arnala I., Kosma V.M., Pikkarainen P., et al. Osteoporosis in adult patients with celiac disease. Bone 1999, 24(3):249-255.
61. DiMatteo M.R. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 2004, 42(3):200-209.
62. Selby W.S., Painter D., Collins A., Faulkner-Hogg K.B., Loblay R.H. Persistent mucosal abnormalities in coeliac disease are not related to the ingestion of trace amounts of gluten. Scand J Gastroenterol 1999, 34(9):909-914.
63. Lanzini A., Lanzarotto F., Villanacci V., Mora A., Bertolazzi S., Turini D., et al. Complete recovery of intestinal mucosa occurs very rarely in adult coeliac patients despite adherence to gluten-free diet. Aliment Pharmacol Ther 2009, 29(12):1299-1308.
64. Tye-Din J.A., Anderson R.P., Ffrench R.A., Brown G.J., Hodsman P., Siegel M., et al. The effects of ALV003 pre-digestion of gluten on immune response and symptoms in celiac disease in vivo. Clin Immunol 2010, 134(3):289-295.
65. Holmes G.K., Stokes P.L., Sorahan T.M., Prior P., Waterhouse J.A., Cooke W.T. Coeliac disease, gluten-free diet, and malignancy. Gut 1976, 17(8):612-619.
66. Nielsen O.H., Jacobsen O., Pedersen E.R., Rasmussen S.N., Petri M., Laulund S., et al. Non-tropical sprue. Malignant diseases and mortality rate. Scand J Gastroenterol 1985, 20(1):13-18.
67. Sjostrom H., Lundin K.E., Molberg O., Korner R., McAdam S.N., Anthonsen D., et al. Identification of a gliadin T-cell epitope in coeliac disease: general importance of gliadin deamidation for intestinal T-cell recognition. Scand J Immunol 1998, 48(2):111-115.
68. van de Wal Y., Kooy Y.M., van Veelen P.A., Pena S.A., Mearin L.M., Molberg O., et al. Small intestinal T cells of celiac disease patients recognize a natural pepsin fragment of gliadin. Proc Natl Acad Sci USA 1998, 95(17):10050-10054.
69. van de Wal Y., Kooy Y.M., van Veelen P., Vader W., August S.A., Drijfhout J.W., et al. Glutenin is involved in the gluten-driven mucosal T cell response. Eur J Immunol 1999, 29(10):3133-3139.
70. Auricchio S., De Ritis G., De Vincenzi M., Occorsio P., Silano V. Effects of gliadin-derived peptides from bread and durum wheats on small intestine cultures from rat fetus and coeliac children. Pediatr Res 1982, 16(12):1004-1010.
71. Molberg O., Uhlen A.K., Jensen T., Flaete N.S., Fleckenstein B., Arentz-Hansen H., et al. Mapping of gluten T-cell epitopes in the bread wheat ancestors: implications for celiac disease. Gastroenterology 2005, 128(2):393-401.
72. van den Broeck H.C., van Herpen T.W., Schuit C., Salentijn E.M., Dekking L., Bosch D., et al. Removing celiac disease-related gluten proteins from bread wheat while retaining technological properties: a study with Chinese Spring deletion lines. BMC Plant Biol 2009, 9:41.
73. Zandonadi R.P., Botelho R.B., Araujo W.M. Psyllium as a substitute for gluten in bread. J Am Diet Assoc 2009, 109(10):1781-1784.
74. Ciacci C., Maiuri L., Caporaso N., Bucci C., Del Giudice L., Rita Massardo D., et al. Celiac disease: in vitro and in vivo safety and palatability of wheat-free sorghum food products. Clin Nutr 2007, 26(6):799-805.
75. Zevallos V.F., Ellis H.J., Suligoj T., Herencia L.I., Ciclitira P.J. Variable activation of immune response by quinoa (Chenopodium quinoa Willd.) prolamins in celiac disease. Am J Clin Nutr 2012, 96(2):337-344.
76. Di Cagno R., De Angelis M., Lavermicocca P., De Vincenzi M., Giovannini C., Faccia M., et al. Proteolysis by sourdough lactic acid bacteria: effects on wheat flour protein fractions and gliadin peptides involved in human cereal intolerance. Appl Environ Microbiol 2002, 68(2):623-633.
77. Di Cagno R., De Angelis M., Auricchio S., Greco L., Clarke C., De Vincenzi M., et al. Sourdough bread made from wheat and nontoxic flours and started with selected lactobacilli is tolerated in celiac sprue patients. Appl Environ Microbiol 2004, 70(2):1088-1096.
78. Di Cagno R., Barbato M., Di Camillo C., Rizzello C.G., De Angelis M., Giuliani G., et al. Gluten-free sourdough wheat baked goods appear safe for young celiac patients: a pilot study. J Pediatr Gastroenterol Nutr 2010, 51(6):777-783.
79. De Angelis M., Rizzello C.G., Fasano A., Clemente M.G., De Simone C., Silano M., et al. VSL#3 probiotic preparation has the capacity to hydrolyze gliadin polypeptides responsible for Celiac Sprue. Biochim Biophys Acta 2006, 1762(1):80-93.
80. Gianfrani C., Siciliano R.A., Facchiano A.M., Camarca A., Mazzeo M.F., Costantini S., et al. Transamidation of wheat flour inhibits the response to gliadin of intestinal T cells in celiac disease. Gastroenterology 2007, 133(3):780-789.
81. Shan L., Molberg O., Parrot I., Hausch F., Filiz F., Gray G.M., et al. Structural basis for gluten intolerance in celiac sprue. Science 2002, 297(5590):2275-2279.
82. Hausch F., Shan L., Santiago N.A., Gray G.M., Khosla C. Intestinal digestive resistance of immunodominant gliadin peptides. Am J Physiol Gastrointest Liver Physiol 2002, 283(4):G996-G1003.
83. Shan L., Marti T., Sollid L.M., Gray G.M., Khosla C. Comparative biochemical analysis of three bacterial prolyl endopeptidases: implications for coeliac sprue. Biochem J 2004, 383(Pt 2):311-318.
84. Stepniak D., Spaenij-Dekking L., Mitea C., Moester M., de Ru A., Baak-Pablo R., et al. Highly efficient gluten degradation with a newly identified prolyl endoprotease: implications for celiac disease. Am J Physiol Gastrointest Liver Physiol 2006, 291(4):G621-G629.
85. Marti T., Molberg O., Li Q., Gray G.M., Khosla C., Sollid L.M. Prolyl endopeptidase-mediated destruction of T cell epitopes in whole gluten: chemical and immunological characterization. J Pharmacol Exp Ther 2005, 312(1):19-26.
86. Pyle G.G., Paaso B., Anderson B.E., Allen D.D., Marti T., Li Q., et al. Effect of pretreatment of food gluten with prolyl endopeptidase on gluten-induced malabsorption in celiac sprue. Clin Gastroenterol Hepatol 2005, 3(7):687-694.
87. Ehren J., Moron B., Martin E., Bethune M.T., Gray G.M., Khosla C. A food-grade enzyme preparation with modest gluten detoxification properties. PLoS One 2009, 4(7):e6313.
88. Mitea C., Havenaar R., Drijfhout J.W., Edens L., Dekking L., Koning F. Efficient degradation of gluten by a prolyl endoprotease in a gastrointestinal model: implications for coeliac disease. Gut 2008, 57(1):25-32.
89. Gass J., Bethune M.T., Siegel M., Spencer A., Khosla C. Combination enzyme therapy for gastric digestion of dietary gluten in patients with celiac sprue. Gastroenterology 2007, 133(2):472-480.
90. Siegel M., Garber M.E., Spencer A.G., Botwick W., Kumar P., Williams R.N., et al. Safety, tolerability, and activity of ALV003: results from two phase 1 single, escalating-dose clinical trials. Dig Dis Sci 2012, 57(2):440-450.
91. Lahdeaho M.L., Maki M., Kaukinen K., et al. ALV003, a novel glutenase, attenuates gluten-induced small intestinal mucosal injury in celiac disease patients: a randomized controlled phase 2A clinical trial. Gut 2011, 60:A12.
92. Korponay-Szabo I.R., Tumpek J., Gyimesi J., Laurila K., Papp M., Maki M., et al. Food-grade gluten degrading enzymes to treat dietary transgressions in coeliac adolescents. J Pediatr Gastroenterol Nutr 2010, 50. E68-E6E.
93. Pinier M., Fuhrmann G., Galipeau H.J., Rivard N., Murray J.A., David C.S., et al. The copolymer P(HEMA-co-SS) binds gluten and reduces immune response in gluten-sensitized mice and human tissues. Gastroenterology 2012, 142(2):316-325. e1-12.
94. van Elburg R.M., Uil J.J., Mulder C.J., Heymans H.S. Intestinal permeability in patients with coeliac disease and relatives of patients with coeliac disease. Gut 1993, 34(3):354-357.
95. Lammers K.M., Lu R., Brownley J., Lu B., Gerard C., Thomas K., et al. Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3. Gastroenterology 2008, 135(1):194-204. e3.
96. Di Pierro M., Lu R., Uzzau S., Wang W., Margaretten K., Pazzani C., et al. Zonula occludens toxin structure-function analysis. Identification of the fragment biologically active on tight junctions and of the zonulin receptor binding domain. J Biol Chem 2001, 276(22):19160-19165.
97. Tripathi A., Lammers K.M., Goldblum S., Shea-Donohue T., Netzel-Arnett S., Buzza M.S., et al. Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2. Proc Natl Acad Sci USA 2009, 106(39):16799-16804.
98. Paterson B.M., Lammers K.M., Arrieta M.C., Fasano A., Meddings J.B. The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. Aliment Pharmacol Ther 2007, 26(5):757-766.
99. Kelly C.P., Green P.H., Murray J.A., Dimarino A., Colatrella A., Leffler D.A., et al. Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study. Aliment Pharmacol Ther 2013, 37(2):252-262.
100. Zhao J., de Vera J., Narushima S., Beck E.X., Palencia S., Shinkawa P., et al. R-spondin1, a novel intestinotrophic mitogen, ameliorates experimental colitis in mice. Gastroenterology 2007, 132(4):1331-1343.
101. Beaurepaire C., Smyth D., McKay D.M. Interferon-gamma regulation of intestinal epithelial permeability. J Interferon Cytokine Res 2009, 29(3):133-144.
102. Utech M., Ivanov A.I., Samarin S.N., Bruewer M., Turner J.R., Mrsny R.J., et al. Mechanism of IFN-gamma-induced endocytosis of tight junction proteins: myosin II-dependent vacuolarization of the apical plasma membrane. Mol Biol Cell 2005, 16(10):5040-5052.
103. Sollid L.M., Khosla C. Novel therapies for coeliac disease. J Intern Med 2011, 269(6):604-613.
104. Jabri B., Sollid L.M. Mechanisms of disease: immunopathogenesis of celiac disease. Nat Clin Pract Gastroenterol Hepatol 2006, 3(9):516-525.
105. Molberg O., McAdam S., Lundin K.E., Kristiansen C., Arentz-Hansen H., Kett K., et al. T cells from celiac disease lesions recognize gliadin epitopes deamidated in situ by endogenous tissue transglutaminase. Eur J Immunol 2001, 31(5):1317-1323.
106. Nanda N., Iismaa S.E., Owens W.A., Husain A., Mackay F., Graham R.M. Targeted inactivation of Gh/tissue transglutaminase II. J Biol Chem 2001, 276(23):20673-20678.
107. De Laurenzi V., Melino G. Gene disruption of tissue transglutaminase. Mol Cell Biol 2001, 21(1):148-155.
108. Korponay-Szabo I.R., Laurila K., Szondy Z., Halttunen T., Szalai Z., Dahlbom I., et al. Missing endomysial and reticulin binding of coeliac antibodies in transglutaminase 2 knockout tissues. Gut 2003, 52(2):199-204.
109. Freund K.F., Doshi K.P., Gaul S.L., Claremon D.A., Remy D.C., Baldwin J.J., et al. Transglutaminase inhibition by 2-[(2-oxopropyl)thio]imidazolium derivatives: mechanism of factor XIIIa inactivation. Biochemistry 1994, 33(33):10109-10119.
110. Maiuri L., Ciacci C., Ricciardelli I., Vacca L., Raia V., Rispo A., et al. Unexpected role of surface transglutaminase type II in celiac disease. Gastroenterology 2005, 129(5):1400-1413.
111. Choi K., Siegel M., Piper J.L., Yuan L., Cho E., Strnad P., et al. Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2. Chem Biol 2005, 12(4):469-475.
112. Watts R.E., Siegel M., Khosla C. Structure-activity relationship analysis of the selective inhibition of transglutaminase 2 by dihydroisoxazoles. J Med Chem 2006, 49(25):7493-7501.
113. Maiuri L., Ciacci C., Ricciardelli I., Vacca L., Raia V., Auricchio S., et al. Association between innate response to gliadin and activation of pathogenic T cells in coeliac disease. Lancet 2003, 362(9377):30-37.
114. Matysiak-Budnik T., Moura I.C., Arcos-Fajardo M., Lebreton C., Menard S., Candalh C., et al. Secretory IgA mediates retrotranscytosis of intact gliadin peptides via the transferrin receptor in celiac disease. J Exp Med 2008, 205(1):143-154.
115. Kapoerchan V.V., Wiesner M., Hillaert U., Drijfhout J.W., Overhand M., Alard P., et al. Design, synthesis and evaluation of high-affinity binders for the celiac disease associated HLA-DQ2 molecule. Mol Immunol 2010, 47(5):1091-1097.
116. Xia J., Bergseng E., Fleckenstein B., Siegel M., Kim C.Y., Khosla C., et al. Cyclic and dimeric gluten peptide analogues inhibiting DQ2-mediated antigen presentation in celiac disease. Bioorg Med Chem 2007, 15(20):6565-6573.
117. Silano M., Di Benedetto R., Trecca A., Arrabito G., Leonardi F., De Vincenzi M. A decapeptide from durum wheat prevents celiac peripheral blood lymphocytes from activation by gliadin peptides. Pediatr Res 2007, 61(1):67-71.
118. Salmi M., Jalkanen S. Molecules controlling lymphocyte migration to the gut. Gut 1999, 45(1):148-153.
119. Berlin C., Berg E.L., Briskin M.J., Andrew D.P., Kilshaw P.J., Holzmann B., et al. Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell 1993, 74(1):185-195.
120. Di Sabatino A., Rovedatti L., Rosado M.M., Carsetti R., Corazza G.R., MacDonald T.T. Increased expression of mucosal addressin cell adhesion molecule 1 in the duodenum of patients with active celiac disease is associated with depletion of integrin alpha4beta7-positive T cells in blood. Hum Pathol 2009, 40(5):699-704.
121. Ghosh S., Goldin E., Gordon F.H., Malchow H.A., Rask-Madsen J., Rutgeerts P., et al. Natalizumab for active Crohn's disease. N Engl J Med 2003, 348(1):24-32.
122. Keshav S., Vanasek T., Niv Y., Petryka R., Howaldt S., Bafutto M., et al. A Randomized Controlled Trial of the Efficacy and Safety of CCX282-B, an Orally-Administered Blocker of Chemokine Receptor CCR9, for Patients with Crohn's Disease. PLoS One 2013, 8(3):e60094.
123. Rashtak S., Marietta E., Murray J. Gliadin Stimulation of Monocytes Leads to Increased Expression of Multiple T Cell Recruiting Chemokines: A Novel Innate Immune Response. Clin Immunol 2010, 135. S47-S4S.
124. Chatenoud L. Immune therapy for type 1 diabetes mellitus - what is unique about anti-CD3 antibodies?. Nat Rev Endocrinol 2010, 6(3):149-157.
125. Herold C., Ganslmayer M., Ocker M., Zopf S., Gailer B., Hahn E.G., et al. Inducibility of microsomal liver function may differentiate cirrhotic patients with maintained compared with severely compromised liver reserve. J Gastroenterol Hepatol 2003, 18(4):445-449.
126. Wiczling P., Rosenzweig M., Vaickus L., Jusko W.J. Pharmacokinetics and pharmacodynamics of a chimeric/humanized anti-CD3 monoclonal antibody, otelixizumab (TRX4), in subjects with psoriasis and with type 1 diabetes mellitus. J Clin Pharmacol 2010, 50(5):494-506.
127. Sandborn W.J., Colombel J.F., Frankel M., Hommes D., Lowder J.N., Mayer L., et al. Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis. Gut 2010, 59(11):1485-1492.
128. Edwards J.C., Szczepanski L., Szechinski J., Filipowicz-Sosnowska A., Emery P., Close D.R., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004, 350(25):2572-2581.
129. Hauser S.L., Waubant E., Arnold D.L., Vollmer T., Antel J., Fox R.J., et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008, 358(7):676-688.
130. Sollid L.M., Molberg O., McAdam S., Lundin K.E. Autoantibodies in coeliac disease: tissue transglutaminase - guilt by association?. Gut 1997, 41(6):851-852.
131. Mei H.E., Frolich D., Giesecke C., Loddenkemper C., Reiter K., Schmidt S., et al. Steady-state generation of mucosal IgA+ plasmablasts is not abrogated by B-cell depletion therapy with rituximab. Blood 2010, 116(24):5181-5190.
132. Pender S.L., Tickle S.P., Docherty A.J., Howie D., Wathen N.C., MacDonald T.T. A major role for matrix metalloproteinases in T cell injury in the gut. J Immunol 1997, 158(4):1582-1590.
133. Ciccocioppo R., Di Sabatino A., Bauer M., Della Riccia D.N., Bizzini F., Biagi F., et al. Matrix metalloproteinase pattern in celiac duodenal mucosa. Lab Invest 2005, 85(3):397-407.
134. Przemioslo R.T., Lundin K.E., Sollid L.M., Nelufer J., Ciclitira P.J. Histological changes in small bowel mucosa induced by gliadin sensitive T lymphocytes can be blocked by anti-interferon gamma antibody. Gut 1995, 36(6):874-879.
135. Bethune M.T., Siegel M., Howles-Banerji S., Khosla C. Interferon-gamma released by gluten-stimulated celiac disease-specific intestinal T cells enhances the transepithelial flux of gluten peptides. J Pharmacol Exp Ther 2009, 329(2):657-668.
136. Gillett H.R., Arnott I.D., McIntyre M., Campbell S., Dahele A., Priest M., et al. Successful infliximab treatment for steroid-refractory celiac disease: a case report. Gastroenterology 2002, 122(3):800-805.
137. Costantino G., della Torre A., Lo Presti M.A., Caruso R., Mazzon E., Fries W. Treatment of life-threatening type I refractory coeliac disease with long-term infliximab. Dig Liver Dis 2008, 40(1):74-77.
138. Hue S., Mention J.J., Monteiro R.C., Zhang S., Cellier C., Schmitz J., et al. A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease. Immunity 2004, 21(3):367-377.
139. Maiuri L., Ciacci C., Auricchio S., Brown V., Quaratino S., Londei M. Interleukin 15 mediates epithelial changes in celiac disease. Gastroenterology 2000, 119(4):996-1006.
140. Meresse B., Chen Z., Ciszewski C., Tretiakova M., Bhagat G., Krausz T.N., et al. Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity 2004, 21(3):357-366.
141. Di Sabatino A., Ciccocioppo R., Cupelli F., Cinque B., Millimaggi D., Clarkson M.M., et al. Epithelium derived interleukin 15 regulates intraepithelial lymphocyte Th1 cytokine production, cytotoxicity, and survival in coeliac disease. Gut 2006, 55(4):469-477.
142. Mention J.J., Ben Ahmed M., Begue B., Barbe U., Verkarre V., Asnafi V., et al. Interleukin 15: a key to disrupted intraepithelial lymphocyte homeostasis and lymphomagenesis in celiac disease. Gastroenterology 2003, 125(3):730-745.
143. Yokoyama S., Watanabe N., Sato N., Perera P.Y., Filkoski L., Tanaka T., et al. Antibody-mediated blockade of IL-15 reverses the autoimmune intestinal damage in transgenic mice that overexpress IL-15 in enterocytes. Proc Natl Acad Sci USA 2009, 106(37):15849-15854.
144. Malamut G., El Machhour R., Montcuquet N., Martin-Lanneree S., Dusanter-Fourt I., Verkarre V., et al. IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease-associated inflammation and lymphomagenesis. J Clin Invest 2010, 120(6):2131-2143.
145. Daveson A.J., Jones D.M., Gaze S., McSorley H., Clouston A., Pascoe A., et al. Effect of hookworm infection on wheat challenge in celiac disease - a randomised double-blinded placebo controlled trial. PLoS One 2011, 6(3):e17366.
146. McSorley H.J., Gaze S., Daveson J., Jones D., Anderson R.P., Clouston A., et al. Suppression of inflammatory immune responses in celiac disease by experimental hookworm infection. PLoS One 2011, 6(9):e24092.
147. Keech C.L., Dromey J., Chen Z.J., Anderson R.P., McCluskey J. Immune Tolerance Induced By Peptide Immunotherapy in An HLA Dq2-Dependent Mouse Model of Gluten Immunity. Gastroenterology 2009, 136(5). A57-A.